COMMUNIQUÉS West-GlobeNewswire

Praxis Precision Medicines to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 19, 2026, and Participate in Upcoming Investor Conferences
09/02/2026
BOSTON, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced it [...]
LifeStance to Host Fourth Quarter and Full Year 2025 Earnings Conference Call on February 25, 2026
09/02/2026
SCOTTSDALE, Ariz., Feb. 09, 2026 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (NASDAQ: LFST), one of the nation’s largest providers of outpatient mental health care, will issue its fourth quarter and full year 2025 [...]
Agomab Announces Closing of Initial Public Offering
09/02/2026
ANTWERP, Belgium, February 9, 2026 (GLOBE NEWSWIRE) – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab”), a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology [...]
PetVivo Sets Fiscal Third Quarter 2026 Conference Call for Monday, February 16, 2026 at 5:00 p.m. ET
09/02/2026
MINNEAPOLIS, MN, US, Feb. 09, 2026 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc., including its wholly-owned subsidiary Petvivo Animal Health, Inc. (OTCQX: PETV; OTCID: PETVW), a leading biomedical company delivering [...]
SpyGlass Pharma Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
09/02/2026
ALISO VIEJO, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma”), a late-stage biopharmaceutical company, today announced the closing of its initial public offering of 10, [...]
OraSure to Announce Fourth Quarter 2025 Financial Results and Host Earnings Call on February 25th
09/02/2026
BETHLEHEM, Pa., Feb. 09, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering fourth quarter 2025 financial results and certain business [...]
Synfini Introduces Integrated Microscale Purification, Delivering Assay-Ready Compounds in Hours Instead of Days
09/02/2026
New Capability Collapses the Design-Make-Test-Analyze (DMTA) Cycle, Accelerating Real SAR Learning with High-purity Compounds for Direct-to-Biology Screening MENLO PARK, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Synfini [...]
Ipsen - January 2026 - Monthly information relative to the total number of voting rights and shares composing the share capital
09/02/2026
Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulation [...]
AB Science announced that the Food and Drug Administration (FDA) granted the status of Minor Use in Major Species (MUMS) for Masivet® in the treatment of canine mast cell tumors
09/02/2026
PRESS RELEASE AB SCIENCE ANNOUNCES THAT THE FDA HAS GRANTED THE STATUS OF MINOR USE IN MAJOR SPECIES DESIGNATION FOR MASIVET IN THE TREATMENT OF CANINE MAST CELL TUMORS AB SCIENCE PRESENTS PERSPECTIVE OF THE ANIMAL [...]
AB Science annonce que la Food and Drug Administration (FDA) américaine a accordé le statut de Minor Use in Major Species (MUMS) au Masivet® dans le traitement des tumeurs mastocytaires chez le chien
09/02/2026
COMMUNIQUÉ DE PRESSE AB SCIENCE ANNONCE QUE LA FDA A ACCORDÉ LE STATUT DE “MINOR USE IN MAJOR SPECIES” (MUMS) AU MASIVET DANS LE TRAITEMENT DES TUMEURS MASTOCYTAIRES CHEZ LE CHIEN AB SCIENCE PRÉSENTE LES PERSPECTIVES DE [...]
Ipsen - Janvier 2026 - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
09/02/2026
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social (conformément à l’article L.233-8 II du Code de commerce et à l’article 223-16 du Règlement Général de l’ [...]
Argá Medtech Reports 94% Lesion Durability and Strong Safety Profile in First-in-Human BURST-AF Trial of Single-Catheter PFA System
09/02/2026
Coherent Sine-Burst Electroporation™ Platform demonstrates 100% procedural success and high freedom from AF in paroxysmal and persistent patients COHERENT-AF U.S. Investigational Device Exemption (IDE) clinical study [...]
The Oxford-Harrington Rare Disease Centre Advances Discovery of Therapies for Friedreich’s Ataxia (FA)
09/02/2026
Philanthropic funding from the FA Alliance Innovation Fund awarded to five Oxford researchers to support development of novel therapeutics OXFORD, UK and CLEVELAND, Ohio, US, 9 th February 2026 – The Oxford-Harrington [...]
Celldex to Present at Upcoming Investor Conferences
09/02/2026
HAMPTON, N.J., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that management will participate in fireside chats at the following upcoming investor conferences: Guggenheim Emerging Outlook: [...]
Trained Therapeutix Discovery Appoints Distinguished Industry Leaders to its Board of Directors
09/02/2026
DALLAS and OSS, The Netherlands, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Trained Therapeutix Discovery, a pioneering immunotherapy biotech company revolutionizing the treatment of immune-mediated diseases through its [...]
Verrica Pharmaceuticals Announces Launch of YCANTH® for the Treatment of Molluscum Contagiosum in Japan by Partner Torii Pharmaceutical
09/02/2026
WEST CHESTER, Pa., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical [...]
ORYZON Announces First Patient Dosed in an Investigator-Initiated Phase Ib Study of Iadademstat in Extensive Stage Small Cell Lung Cancer
09/02/2026
Exploring the combination with atezolizumab and radiation therapy Study led by Yale University MADRID, Spain and CAMBRIDGE, Mass., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), [...]
4DMT Completes Enrollment for 4FRONT-1 Phase 3 Clinical Trial of 4D-150 in Wet AMD
09/02/2026
Enrollment for 4FRONT-1, the first registrational trial for 4D-150 in wet AMD, was completed within an approximately 11-month period, ahead of initial projections 4FRONT-1 overenrolled and expected to exceed 500 [...]
Solid Biosciences Announces Positive Feedback from Type C Meeting with FDA for SGT-003 Gene Therapy for Duchenne Muscular Dystrophy
09/02/2026
- IMPACT DUCHENNE: Company aligned with FDA on Phase 3 randomized, double-blind, placebo-controlled trial design - - IMPACT DUCHENNE: Company anticipates first participant dosing in Q1 2026 - - Company plans for [...]

Pages